Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8-12 weeks' exemestane exposure for ER+/HER2-postmenopausal breast cancer patients (JBCRG-11TC) |
Hiroyuki Yasojima, Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, and Masakazu Toi |
2018.12 SABCS Poster San Antonio, USA |
A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06 / EMERALD) |
Norikazu Masuda, Toshinari Yamashita, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, Yasuyuki Kojima, Yasuaki Sagara, Hiroshi Tada, Tsutomu Iwasa, Takayuki Kadoya, Tsuguo Iwatani, Hiroki Hasegawa, Satoshi Morita, Shinji Ohno |
2018.12 SABCS Poster San Antonio, USA |
Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study. |
Akihiko Shimomura, Norikazu Masuda, Junpei Kawauchi, Satoko Takizawa, Makiko Ichikawa, Juntaro Matasuzaki, Katsumasa Kuroi, Hisato Hara, Naohito Yamamoto, Kenichi Inoue, Nobuyasu Suganuma, Kenjiro Aogi, Shinji Ohno, Kenji Tamura, Takahiro Ochiya, Masakazu Toi |
2018.12 SABCS Poster San Antonio, USA |
Evaluation of the safety of neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with docetaxel and cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-11TC) |
Koji Kaneko, Nobuaki Sato, Hiroyuki Yasojima, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi |
第56回日本癌治療学会学術集会 Yokohama, JAPAN 2018年10月 |
TrastuzumabとPertuzumabの同時混合点滴の安全性に関する検討 (JBCRG-20 sub-study) |
坂東裕子、増田慎三、伊藤良則、石田和茂、井口研子、水谷麻紀子、小林 心、柏葉匡寛、八十島宏行、笠井宏委、高須賀剛、森田智視、大野真司、戸井雅和 |
第26回日本乳癌学会学術集会 Kyoto, JAPAN 2018年5月 |
閉経後ER陽性進行・再発乳癌におけるフルベストラントの至適投与方法の検討(JBCRG-C06: Safari) |
川口英俊、増田慎三、中山貴寛、青儀健二郎、阿南敬生、伊藤良則、大谷彰一郎、佐藤信昭、佐治重衡、徳永えり子、中村清吾、長谷川善枝、藤澤知巳、山口美樹、山下年成、山本豊、森田智視、大野真司、戸井雅和 |
第26回日本乳癌学会学術集会 Kyoto, JAPAN 2018年5月 |
Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE) |
M. Kashiwaba, Y. Yamamoto, H. Yamashiro, N. Kondo, R. Nakamura, M. Takahashi, U. Toh, K. Tsugawa, K. Narui, K. Tamaki, T. Yoshinami, S. Ohtani, Y. Kai, T. Takano, Y. Yanagita, S. Morita, M. Toi, S. Ohno. |
2018.3 EBCC Poster Barcelona, Spain |
Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer (JBCRG-M03) |
Hidetoshi Kawaguchi, Toshinari Yamashita, Norikazu Masuda, Masahiro Kitada, Kazutaka Narui, Masaya Hattori, Tetsuhiro Yoshinami, Nobuki Matsunami, Kazuhiro Yanagihara, Teru Kawasoe, Takeshi Nagashima, Hiroko Bando, Hiroshi Yano, Yoshie Hasegawa, Rikiya Nakamura, Masahiro Kashiwaba, Satoshi Morita, Shinji Ohno, Masakazu Toi |
2017.12 SABCS Poster San Antonio, USA |
New quantitative diagnostic method by fluorescence nanoparticle for HER2 positive breast cancer treated with neoadjuvant lapatinib and trastuzumab: The Neo-LaTH study (JBCRG-16TR) |
Hiroshi Tada, Minoru Miyashita, Kohsuke Gonda, Mika Watanabe, Akihiko Suzuki, Go Watanabe, Narumi Harada, Akiko Sato, Yohei Hamanaka, Norikazu Masuda, Masakazu Toi, Shinji Ohno, Hiroko Bando, Hiroshi Ishiguro, Kenichi Inoue, Naohito Yamamoto, Katsumasa Kuroi, Noriaki Ohuchi and Takanori Ishida |
2017.12 SABCS Poster San Antonio, USA |
Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer |
Norikazu Masuda, Nobuaki Sato, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi |
2017.12 SABCS poster San Antonio, USA |
閉経後HR乳癌患者に対するレスポンスガイド下術前内分泌療法 (JBCRG-11CPA) |
森本 卓,佐藤 信昭,増田 慎三,上野 貴之,神林智寿子、金子耕司、八十島宏行、佐藤 友威、新宮 聖士、田邊 匡、尾崎 慎治、笹野 公伸、森田 智視、大野 真司,戸井 雅和 |
2017年10月 第55回日本癌治療学会学術集会 ワークショップ |
Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20) |
Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Eiji Suzuki, Rikiya Nakamura, Hiroko Bando, Yoshinori Ito, Kazushige Ishida, Takashi Yamanaka, Katsumasa Kuroi, Hiroyuki Yasojima, Hiroi Kasai, Tsuyoshi Takasuka, Takaki Sakurai, Tatsuki R. Kataoka, Satoshi Morita, Shinji Ohno, Masakazu Toi |
2017.9 ESMO Poster Madrid |
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer: A subgroup analysis (JBCRG-C06) |
Kenjiro Aogi, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano Eriko Tokunaga, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno |
2017.9 ESMO Poster Madrid |
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03) |
Kazutaka Narui, Toshinari Yamashita, Masahiro Kitada, Hidetoshi Kawaguchi, Masaya Hattori, Tetsuhiro Yoshinami, Nobuki Matsunami, Kazuhiro Yanagihara, Teru Kawasoe, Takeshi Nagashima, Hiroko Bando, Hiroshi Yano, Yoshie Hasegawa, Rikiya Nakamura, Masahiro Kashiwaba, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi |
2017年6月 ASCO Poster Chicago |
Phase I/II pharmacokinetics/pharmacodynamics study of irinotecan and S-1 for recurrent/metastatic breast cancer in patients with select UGT1A1 genotypes (The JBCRG-M01 study) |
Shigehira Saji, Hiroshi ishiguro, Shogo Nomura, Hiroji Iwata, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi, Japan Breast Cancer Research Group |
2016.10 ESMO Poster Copenhagen |
Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH |
Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Oogami Masahiro, Honma Masato, Satoru Shimizu, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoshi Morita, Masakazu Toi |
2016.12 SABCS Poster San Antonio, Texas |
Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17). |
Naoto Kondo, Yoshinori Ito, Ippei Fukada, Shoichiro Ohtani, Masaya Hattori, Eriko Tokunaga, Nobuki Matsunami, Kohjiro Mashino, Taijiro Kosaka, Masahiko Tanabe, Daisuke Yotsumoto, Kosho Yamanouchi, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Katsumasa Kuroi, Satoshi Morita, Shinji Ohno, Masakazu Toi, Norikazu Masuda |
2016 ASCO Poster |
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy (JBCRG-M05). |
Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama, Naoki Niikura, Fumitaka Hara, Tomomi Fujisawa, Tetsuhiro Yoshinami, Shigehira Saji, Toshimi Takano, Norikazu Masuda, Satoshi Morita, Masakazu Toi, Shinji Ohno. |
2016 ASCO Poster |
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16) |
Kosuke Kawaguchi, Eiji Suzuki, Tatsuki R Kataoka, Masahiro Hirata, Shinji Ohno, Hiroko Bando, Hiroshi Ishiguro, Kenichi Inoue, Naohito Yamamoto, Katsumasa Kuroi, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Japan Breast Cancer Research Group (JBCRG) |
2016 ASCO Poster |
周術期トラスツズマブ治療歴を有する再発乳癌におけるトラスツズマブ投与の観察研究(JBCRG-C02) |
澤木正孝、山城大泰、増田慎三、奥村恭博、高野利実、徳永えり子、齊藤毅、相良安昭、山崎弘資、保野慎治、森田智視、大野真司、戸井雅和 |
第24回 日本乳癌学会学術集会 厳選口演1 (薬物療法) |
HER2陰性進行再発乳癌に対するベバシズマブとパクリタキセル併用療法の観察研究(中間報告;JBCRG-C05) |
中村力也、近藤直人、山本豊、山城大泰、柏葉匡寛、高橋將人、唐宇飛、津川浩一郎、成井一隆、玉城研太朗、吉波哲大、大谷彰一郎、甲斐裕一郎、高野利実、柳田康弘、森田智視、大野真司、戸井雅和 |
第24回 日本乳癌学会学術集会 パネルディスカッション3 (乳癌分子標的薬剤) |
フルベストラントの長期奏効群を探索する多施設共同後方視コホート研究;JBCRG-C06 Safari試験 |
服部正也、川口英俊、増田慎三、中山貴寛、青儀健二郎、阿南敬生、伊藤良則、大谷彰一郎、佐藤信昭、佐治重衡、徳永えり子、中村清吾、長谷川善枝、藤澤知巳、山口美樹、山下年成、山本豊、森田智視、大野真司、戸井雅和 |
第24回 日本乳癌学会学術集会 厳選口演1(薬物療法) |
Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE) |
Naoto Kondo, Yutaka Yamamoto, Hiroyasu Yamashiro, Masahiro Kashiwaba, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno |
2016 EBCC Poster |
Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari) |
Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji,Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Shinji Ohno, Masakazu Toi |
2016 EBCC Poster |
Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients (JBCRG-12,15) |
Shinji Ohno, Hiroshi Ishiguro, Yutaka Yamamoto, Shintaro Takao, Nobuaki Sato, Tomomi Fujisawa, Takayuki Kadoya, Katsumasa Kuroi, Hiroko Bando, Yasufumi Teramura, Hiroji Iwata, Shiro Tanaka, Masakazu Toi |
2015 SABCS Poster |
CREATE-X (JBCRG-04): A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X , JBCRG-04) |
Soo-Jung Lee, Masakazu Toi, Eun Sook Lee, Shoichiro Ohtani, Young-Hyuck Im, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shintaro Takao, Shinji Ohno, Kenjiro Aogi, Hiroji Iwata, Aeree Kim, Hironobu Sasano, Isao Yokota, Yasuo Ohashi, Norikazu Masuda |
2015 SABCS Oral |
医師主導治験の実施体制と課題について(JBCRG-Q06) |
笠井 宏委,青儀 健二郎,坂東 裕子,大谷 彰一郎,津川 浩一郎,森岡 由香,山口 ひとみ,吉波 哲大,相馬 道郎,橋本 郁子,増田 慎三,大野 真司 |
2015年12月 日本臨床薬理学会学術総会 ポスター発表 |
Phase Ib dose-escalation study of Eribulin (Eri) in combination with Gemcitabine (GEM) in patients (pts) with metastatic breast cancer (MBC) (JBCRG-18Gem) |
Masahiro Kashiwaba, Risa Goto, Naoto Kondo, Masaya Hattori, Hiroji Iwata |
2015年10月 日本がん治療学会 FACO International Workshop 口演 |
Phase Ib dose-escalation study of eribulin plus capecitabine in metastatic breast cancer (JBCRG-18Cape) |
Hiroshi Ishiguro, Norikazu Masuda, Hiroyuki Yasojima, Shoichiro Ohtani, Akiyo Yoshimura, Masaya Hattori, Hiroji Iwata |
2015年10月 日本がん治療学会 ポスター発表 |
医師主導治験の実施体制整備状況と課題について(JBCRG-Q06) |
坂東裕子, 青儀健二郎, 大谷彰一郎, 笠井宏委, 津川浩一郎, 森 岡由香,山口ひとみ, 吉波哲大, 相馬道郎, 橋本郁子, 増田慎三, 戸井雅和, 大野真司 |
2015年10月 日本がん治療学会 ワークショップ 口演 |
Impact of lapatinib (La) treatment duration and endocrine therapy (ET) addition on the efficacy of primary dual HER2 blockage with La and trastuzumab (T) for HER2+ breast cancer (BC) patients (pts) |
Hiroko Bando, Norikazu Masuda, Rikiya Nakamura, Naoto Kondo, Katsumasa Kuroi, Mayumi Ishida, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Yasuhiro Yanagita, Hiroshi Ishiguro, Satoru Shimizu, Kenjiro Aogi, Sadao Amano, Shinji Ozaki, Akiko Iguchi-Manaka, Hiroi Kasai, Satoshi Morita, Tastuki R. Kataoka, Masakazu Toi |
2015 ECCO Poster |
Primary systemic therapy by dual HER2 blockage with lapatinib (La) + trastuzumab (T) for Japanese patients (pts) with HER2+ breast cancer (BC): Association of La toxicity and dose with treatment efficacy |
Toshinari Yamashita, Norikazu Masuda, Naohito Yamamoto, Naoto Kondo, Hiroko Bando, Sayuri Akiyoshi, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Tomomi Fujisawa, Hiroshi Ishiguro, Hirotaka Nakayama, Kenjiro Aogi, Sadao Amano, Shinji Ozaki, Hiroyuki Yasojima, Hiroi Kasai, Tastuki R. Kataoka, Satoshi Morita, Masakazu Toi |
2015 ECCO Poster |
閉経後ER陽性進行再発乳癌におけるフルベストラントの至適投与方法の検討(JBCRG-C06:Safari試験) |
川口英俊、増田慎三、中山貴寛、山本豊、佐治重衡、大谷彰一郎、長谷川善枝、山下年成、森田智視、大野真司 |
2015/7 日本乳癌学会 ポスター発表 |
HER2陰性局所進行乳癌に対するアンスラサイクリン-タキサン-エリブリン逐次療法の有用性確認試験(JBCRG-17) |
増田慎三、深田一平、近藤直人、大谷彰一郎、服部正也、小坂泰二郎、田辺真彦、増野浩二郎、松並展輝、澤木正孝、柏葉匡寛、川端英孝、相良安昭、黒井克昌、大野真司、戸井雅和、伊藤良則、森田智視 |
2015/7 日本乳癌学会 ポスター発表 |
HER2陽性乳癌における術前Dual-HER2 blockage 療法±ホルモン療法の検討(Neo-LaTH, JBCRG-16試験) |
山本尚人、増田慎三、近藤直人、坂東裕子、黒井克昌、大野真司、宮本健志、檜垣健二、高野利実、井上賢一、中村力也、清水哲、石黒洋、青儀健二郎、天野定雄、山城大泰、笠井宏委、森田智視、桜井孝規 、戸井雅和 |
2015/7 日本乳癌学会 シンポジウム |
Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer |
Hiroji Iwata, Naohito Yamamoto, Norikazu Masuda, Hiroko Bando, Katsumasa Kuroi, Shinji Ohno, Hiroi Kasai, Satoshi Morita, Takaki Sakurai, Masakazu Toi |
St.Gallen Poster |
術前薬物療法概論 |
黒井克昌* 、戸井雅和、大野真司、中村清吾、岩田広治、増田 慎三、佐藤信昭、津田 均、黒住昌史、秋山 太 |
第22回 日本乳癌学会 2014 シンポジウム1 |
通院化学療法を受ける乳癌患者に対する治療当日の看護師のリスクマネジメント |
金澤麻衣子、増田慎三、黒井克昌、阿部恭子、戸井雅和 |
第22回 日本乳癌学会 2014 ポスター発表、ポスターディスカッション |
Bevacizumab plus Paclitaxel optimization study with interventional maintenance endocrine therapyin advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial, ASCO 2014 |
Shigehira Saji, Masakazu Toi, Takashi Ishikawa, Takanori Ishida, Shoichiro Ohtani, Masahiro Kashiwaba,Yasuaki Sagara, Shigenori Nagai, Yoshie Hasegawa, Tomomi Fujisawa, Norikazu Masuda, Koji Matsumoto,Yutaka Yamamoto, Hiroshi Yoshibayashi, Naruto Taira, Satoshi Morita, Shinji Ohno |
2014 ASCO Poster (trial in progress) |
Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04) |
Shoichiro Ohtani, Norikazu Masuda, Young-Hyuck Im, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shintaro Takao, Shinji Ohno, Kenjiro Aogi, Hiroji Iwata, Katsuhide Yoshidome, Reiki Nishimura, Eun Sook Lee, Isao Yokota, Yasuo Ohashi, Soo-Jung Lee, Masakazu Toi |
2013 SABCS Poster |
A randomized study of docetaxel + cyclophosphamide (TC), 5-fluorouracil + epirubicin + cyclophosphamide (FEC)-TC, and TC-FEC as preoperative chemotherapy for hormone receptor-positive and HER2-negative primary breast cancer: Japan Breast Cancer Research Group (JBCRG) - 09 |
Nobuaki Sato, Norikazu Masuda, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka, and Masakazu Toi |
2013 SABCS Poster |
Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study) |
Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katsumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yasuhiro Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita, Masakazu Toi |
2013 SABCS Poster |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (JBCRG-13) |
Kenji Higaki, Norikazu Masuda, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani,Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi |
2013 ASCO Poster |
Safety of trastuzumab in HER2 positive primary breast cancer in Japan; Initial safety report for the large scale cohort study (JBCRG-C01) |
N. Yamamoto, H. Yamashiro, H. Iwata, N. Masuda, S. ohtani, M. Takahashi, K. Yamazaki, M. Kato, S. Ohno, K. Kuroi, K. Yamagami, T. Morimoto, Y. Hasegawa, T. Takano, H. Shigematsu, M. Hosoda, H. Abe, S. Morita, S. Yasuno, M. Toi |
2013 ASCO Poster |
Cohort study evaluating trastuzumab in HER2 positive early breast cancer in Japan; JBCRG-C01 |
N. Masuda, H. Yamashiro, H. Iwata, R. Nishimura, N. Sato, T. Kamio, T. Saito, T. Lee, S. Yasuno, M. Toi |
St Gallen 2013, 3 |
JBCRG-Q03 通院化学療法を受ける乳がん患者へのリスクマネジメントに関する調査 |
金澤麻衣子、増田慎三、黒井克昌、阿部恭子、戸井雅和、一般社団法人JBCRG(Japan Breast Cancer Research Group) |
第21回日本乳癌学会学術集会、poster、浜松、2013 |
A Prospective Multicenter Randomized Phase II Neo-Adjuvant Study of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Docetaxel, Cyclophosphamide and Trastuzumab (TCH) Versus TCH Followed by FEC Versus TCH Alone, in Patients (pts) with Operable HER2 Positive Breast Cancer: JBCRG-10 Study |
Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M |
2012 SABCS Poster Session 1 |
Inter-observer concordance of Ki-67 labeling index inbreast cancer[br]: Japan Breast Cancer Research Group (JBCRG) Ki-67 Ring Study |
T Ueno, Y Mikami, K Yoshimura, H Tsuda, M Kurosumi, S Masuda, R Horii, M Toi, and H Sasano |
2012 SABCS Poster Session 5 |
ドセタキセルにより惹起される皮膚毒性とステロイド剤およびH2拮抗薬との関連性:多施設共同調査 |
河口浩介、石黒洋、森田智視、中村清吾、大野真司、増田慎三、岩田広治、青儀健二郎、黒井克昌、戸井雅和 |
第10回日本臨床腫瘍学会学術集会、一般口演、大阪、2012年7月 |
通院化学療法を受ける乳がん患者へのリスクマネジメントに関する現状と課題 |
金澤麻衣子、増田慎三、黒井克昌、阿部恭子、戸井雅和 |
第20回日本乳癌学会学術総会、一般演題(示説)、熊本、2012年6月 |
JBCRG10年のあゆみと展望 |
黒井克昌 |
広島大学医学部 広仁会館2階 大会議室 |
A multicenter phase II trial of neoadjuvant letrozole plus low dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): the efficacy and its correlation with circulating endothelial cells. |
上野貴之、増田慎三、神垣俊二、森本卓、中村清吾、黒井克昌、岩田広治、大野真司、田中直、戸井雅和 |
2011 American Society of Clinical Oncology, Chicago (USA), Jun. 2011 |
Update HER2 Therapy for Breast Cancer(乳癌HER2療法の最新知見) |
Dr. Jose Baselga, M.D., Ph.D. |
33rd San Antonio Breast Cancer Symposium, Meet the Experts, San Antonio(USA), Dec.2010 |
国際共同研究SUPREMOへの参加から我が国における乳房切除術後放射線治療の適応を探る |
黒井克昌、増田慎三、青儀健二郎、岩田広治、上野貴之、大野真司、柏葉匡寛、佐藤信昭、中村清吾、中山貴寛、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
第18回日本乳癌学会学術総会、示説討論、札幌、2010年6月 |
JBCRGにおける臨床試験成功の秘訣と今後の展望 |
増田慎三、青儀健二郎、岩田広治、上野貴之、大野真司、柏葉匡寛、黒井克昌、佐藤信昭、中村清吾、中山貴寛、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
第18回日本乳癌学会学術総会、プレジデンシャルシンポジウム、札幌、2010年6月 |
A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study). |
増田慎三、戸井雅和、上野貴之、青儀健二郎、岩田広治、大野真司、黒井克昌、佐藤信昭、中村清吾; Japan Breast Cancer Research Group (JBCRG) |
2010 American Society of Clinical Oncology, Chicago (USA), Jun. 2010 |
Comparison of Molecular characterization of ER+early-stage cancer by standardized quantitative RT-PCR analysis between Japanese and North American populations. |
増田慎三、山中竹春、岩田広治、大野真司、中村清吾、柏葉匡寛、神垣俊二、青儀健二郎、上野貴之、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
ASCO Breast, San Francisco, USA, 2009年10月 |
JBCRG における乳癌術前薬物療法の経験から得た新規治療法開発の展望 |
増田慎三、青儀健二郎、岩田広治、上野貴之、大野真司、柏葉匡寛、黒井克昌、佐藤信昭、中村清吾、中山貴寛、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
第47回日本癌治療学会(横浜)シンポジウム16 新薬導入による乳癌治療の新たなる展開, 2009 |
UGT1A1遺伝子多型を考慮したCPT-11/S-1併用療法の第I/II相臨床試験(JBCRG-M01) |
佐治重衡、石黒 洋、岩田広治、中村清吾、黒井克昌、大野真司、増田慎三、山中竹春、佐々木康綱、稲本 俊、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
第17回日本乳癌学会学術総会、シンポジウム、東京、2009年7月 |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey |
河口浩介、石黒 洋、森田智視、中村清吾、大野真司、増田慎三、岩田広治、青儀健二郎、黒井克昌、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
2009 American Society of Clinical Oncology, New Orleans (USA), Jun. 2009 |
The first report of the association between the recurrence score and risk of recurrence in Japanese population (JBCRG-TR03) |
Toi M, Iwata H, Masuda N, Ohno S, Nakamura S, Yamanaka T, Nakayama T,Kashiwaba M, Kamigaki S, Aogi K, Ueno T, Kuroi K: Japan Breast Cancer Research Group (JBCRG) |
京都乳癌コンセンサス会議 2009 国際大会、京都、2009年4月 |
術前化学療法における治療効果予測因子としてのHER2/TOPO IIα解析の意義 (JBCRG-TR01) |
堀口慎一郎、黒井克昌、高橋將人、山下啓子、佐藤信昭、岩田広治、増田慎三、中村清吾、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
第16回日本乳癌学会総会、口演、大阪、2008年9月 |
JBCRG03: Docetaxel 75 followed by FEC 100による術前化学療法 |
山本尚人、岩田広治、佐藤信昭、増田慎三、中村清吾、黒井克昌、黒住昌史、津田均、秋山太、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
第16回日本乳癌学会、シンポジウム2(術前薬物療法の現状と展望)、大阪、2008年9月 |
臨床試験における検体を用いたトランスレーショナルリサーチ(TR)推進のための新システム |
片岡明美、大野真司、戸井雅和、中村清吾、黒井克昌、岩田広治、遠山竜也、増田慎三、徳永えり子、堀口和美;Japan Breast Cancer Research Group (JBCRG) |
第108回日本外科学会学術集会、長崎、2008年5月 |
Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: Results of a multicenter phase II trial: JBCRG03 trial |
Sato N, Iwata H, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Toi M; Japan Breast Cancer Research Group (JBCRG) |
6th European Breast Cancer Conference, Poster, Berlin (Germany), Apr. 2008 |
JBCRG03: Docetaxel followed by FEC 100 による術前化学療法 - JBCRG01,02からのreviewとbreakthrough - |
柏葉 匡寛、若林 剛、中村清吾、黒井克昌、岩田広治、大野真司、増田慎三、佐藤信昭、麻賀太郎、山本尚人、青儀健二郎、佐藤康幸、黒住昌史、津田 均、秋山 太、戸井雅和; Japan Breast Cancer Research Group (JBCRG) |
第15回日本乳癌学会、プレジデンシャルシンポジウム2、横浜、2007年6月 |
トランスレーショナルリサーチ推進のためのネットワーク構築 |
片岡明美、大野真司、戸井雅和、中村清吾、黒井克昌、岩田広治、遠山竜也、増田慎三、徳永えり子;Japan Breast Cancer Research Group (JBCRG) |
第15回日本乳癌学会、口演、横浜、2007年6月 |
JBCRG02: 原発乳がんに対するFEC 100 followed by Docetaxel 100による術前化学療法 |
濱岡 剛、中村清吾、増田慎三、岩田広治、黒井克昌、黒住昌史、津田 均、秋山 太、戸井雅和;Japan Breast Cancer Research Group (JBCRG) |
第15回日本乳癌学会、口演、横浜、2007年6月 |
Significance of HER2 for predicting pathological complete response to preoperative treatment with FEC followed by docetaxel |
Toi M, Nakamura S, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F;Japan Breast Cancer Research Group (JBCRG). |
29th San Antonio Breast Cancer Symposium, Poster, San Antonio (USA), Dec. 2006 |
Premature ovarian disfunction induced by neopadjuvantr chemotherapy (FEC followed by docetaxel) for breast cancer |
Shinano Hitomi, Hamaoka Tsuyoshi, Nakamura Seigo, Toi Masakazu, Kuroi Katsumasa; Japan Breast Cancer Research Group (JBCRG). |
3rd Organisation for Oncology and Translational Research, Hong Kong, Oral, Sep. 2006 |
原発乳癌に対するFEC followed by docetaxel 100による術前化学療法-JBCRG02- |
中村清吾、増田慎三、岩田広治、戸井雅和、黒井克昌、秋山 太; Japan Breast Cancer Research Group (JBCRG) |
第14回日本乳癌学会、金沢、2006年7月 |
原発乳癌に対する術前化学療法 特にpCRの判定とJBCRGの取り組み |
黒井克昌、中村清吾、戸井雅和、岩田広治、日馬幹弘、増田慎三、辛 栄成、大野真司、山崎弘資、高塚雄一、久松和史、柏葉匡寛、佐藤康幸、海瀬博史、秋山 太、津田 均、黒住昌史; Japan Breast Cancer Research Group (JBCRG) |
第106回日本外科学会、東京、2006年3月 |
The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer. |
Nakamura S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG) |
5th European Breast Cancer Conference, Nice (France), Mar. 2006 |
Feasibility and efficacy of phase II trial of sequential preoperative FEC 100 followed by Docetaxel 100 in primary operable breast cancer. |
Nakamura S, Masuda N, Iwata H, Toi M, Kuroi K, Akiyama F; Japan Breast Cancer Research Group (JBCRG) |
2nd Organisation for Oncology and Translational Research, Tokyo, Nov. 2005 |
原発性乳癌術前化学療法におけるsupportive careの現状と工夫 |
増田慎三、中村清吾、戸井雅和、岩田広治、大野真司、高塚雄一、久松和史、山崎弘資、日馬幹弘、海瀬博史、佐藤康幸、柏葉匡寛、辛 栄成、黒井克昌、秋山 太、津田 均、黒住昌史; Japan Breast Cancer Research Group(JBCRG) |
第13回日本乳癌学会、倉敷、2005年6月 |
The effect of Pathological Response of Multicenter phase II trial of sequential FEC followed by docetaxel in primary operable breast cancer – interim analysis - |
Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
27th San Antonio Breast Cancer Symposium, Poster, SanAntonio (USA), Dec. 2004 |
Multiphase II trial of sequential FEC followed by docetaxel in primary operative breast cancer. 90例について臨床効果、効果安全性について発表 |
Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
1st Organisation for Oncology and Translational Research, Hong Kong, Oct. 2004 |
Unargued issues on the pathological assessment of response in primary sytemic therapy for breast cancer. 病理組織判定における問題点について発表 |
Kuroi K, Toi M, Takatsuka Y, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG). |
1st Organisation for Oncology and Translational Research, Hong Kong, Oct. 2004 |
原発乳癌に対するCEF followed by Docetaxel併用療法による術前化学療法の検討 |
岩田広治、中村清吾、戸井雅和、辛 栄成、増田慎三、大野真司、高塚雄一、久松和史、山崎弘資、日馬幹弘、海瀬博史、佐藤康幸、黒井克昌、秋山 太、津田 均、黒住昌史; Japan Breast Cancer Research Group (JBCRG) |
第12回日本乳癌学会、小倉、2004年6月 |
Cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF - DOC) as preoperative chemotherapy in primary operable breast cancer. |
Nakamura S, Ohno S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Hisamatsu K, Yamazaki K, Masuda N, Akiyama F; Japan Breast Cancer Research Group (JBCRG) |
2004 American Society of Clinical Oncology, New Orleans (USA), Jun. 2004 |
Cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF - DOC) as preoperative chemotherapy in primary operable breast cancer. |
Kuroi K, Toi M, Takatsuka Y, Iwata H, Ohno S, Kusama M, Shin E, Hisamatsu K, Yamazaki K, Sato Y, Masuda N, Kaise H, Akiyama F, Nakamura S; Japan Breast Cancer Research Group (JBCRG) |
15th International Congress on Anti Cancer Treatment, Paris (France), Feb. 2004 |
原発乳癌に対するCEF followed by Docetaxel併用療法による術前化学療法の検討 |
辛 栄成、中村清吾、戸井雅和、高塚雄一、佐藤康幸、大野真司、岩田広治、日馬幹弘、久松和史、海瀬博史、山崎弘資、黒井克昌、秋山 太; Japan Breast Cancer Research Group (JBCRG) |
第41回日本癌治療学会、口演、札幌、2003年10月 |
原発乳癌に対するCEF followed by Docetaxel併用療法による術前化学療法の検討 |
黒井克昌、戸井雅和、高塚雄一、大野真司、岩田広治、日馬幹弘、辛 栄成、佐藤康幸、山崎弘資、久松和史、秋山 太、中村清吾; Japan Breast Cancer Research Group (JBCRG) |
第11回日本乳癌学会、口演、新潟、2003年6月 |